Protara Therapeutics
TARA
29 hedge funds and large institutions have $16.9M invested in Protara Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.
15% more capital invested
Capital invested by funds: $14.6M → $16.9M (+$2.25M)
0.2% more ownership
Funds ownership: 48.46% → 48.66% (+0.2%)
3% less funds holding
Funds holding: 30 → 29 (-1)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
50% less call options, than puts
Call options by funds: $1K | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$193K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$104K |
| 3 |
LPL Financial
San Diego,
California
|
+$33.1K |
| 4 |
BlackRock
New York
|
+$2.42K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$123K |
| 2 |
Two Sigma Advisers
New York
|
-$51.6K |
| 3 |
Two Sigma Investments
New York
|
-$34.4K |
| 4 |
Renaissance Technologies
New York
|
-$26.7K |
| 5 |
Millennium Management
New York
|
-$10.9K |
TARA Hedge Fund Activity: Q1 2023 in Review
29 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2023, worth a combined $16.9M — up 15% from $14.6M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TARA and 2 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.
The largest buyer was Morgan Stanley, adding an estimated $193K. The largest seller was OrbiMed, cutting an estimated $123K.
- 29 institutional investors held Protara Therapeutics (TARA) as of Q1 2023, down from 30 in Q4 2022.
- Funds reported $16.9M of Protara Therapeutics stock for Q1 2023, up 15% quarter-over-quarter.
- 2 funds opened new Protara Therapeutics positions in Q1 2023 and 3 closed out, a net change of -1 holder.
- The largest Protara Therapeutics buyer in Q1 2023 was Morgan Stanley, an estimated $193K added.
- The largest Protara Therapeutics seller in Q1 2023 was OrbiMed, an estimated $123K sold.
Based on aggregated 13F filings for Q1 2023.